Phapros Net Profit Surges 113 Percent

PT Phapros Tbk recorded a surge in net profit for the first quarter of 2026 after successfully maintaining sales growth and cost efficiency. This performance extends the company’s recovery trend since last year. The state-owned pharmaceutical firm reversed its position from a loss to a profit in the same period. Acting President Director of Phapros, Ida Rahmi Kurniasih, stated that this achievement was supported by increased sales and cost control. “Phapros’s profitability in the first quarter of 2026 was supported by a 10.17 percent increase in sales to Rp221.09 billion compared to the same period last year of Rp200.67 billion,” said Ida on Friday (24/4/2026). She noted that sales growth higher than production costs drove the rise in gross profit. Cost of goods sold only increased by 5.04 percent, while operating expenses rose 7.35 percent year-on-year. Ida said cost stability was a key factor in maintaining profitability. “In addition to maintaining COGS stability, Phapros’s operating expenses for January-March 2026 were also relatively stable, rising only 7.35 percent year-on-year,” said Ida. With these conditions, Phapros recorded a net profit of Rp761.49 million, reversing from a loss of Rp5.92 billion in the same period the previous year. Cash flow also improved with a positive position of Rp37.2 billion, up from minus Rp19.6 billion. Ida said this performance shows the company is able to adapt amid global pressures. “Amid global dynamics full of uncertainty, Phapros has been able to maintain good financial performance, thus successfully recording net profit,” said Ida. According to Ida, the company’s strategy focuses on optimising sales channels, maintaining product availability, and cost efficiency across all lines. The company also carried out risk mitigation against rising raw material prices through purchase contracts from the beginning of the year. Ida said mitigation steps were taken to maintain production cost stability. “In response to the impact of geopolitics causing rises in material prices and costs, we have already carried out risk mitigation with purchase contracts from the beginning of the year and continue to monitor developments to remain adaptive,” said Ida. One of the main supports for growth came from the branded generic drug segment, which recorded a significant surge. Sales in this segment rose 59 percent to Rp128.70 billion compared to the same period last year of Rp80.88 billion. The company also recorded contributions from anti-tuberculosis drugs and blood-boosting tablets as part of support for government health programmes, including the handling of TB, anaemia, and stunting.